Latest Topics on Novel Imeglimin with Various Mechanism and Safety for Oral Hypoglycemic Agent (OHA)

A novel imeglimin (Twymeeg) was developed as an oral hypoglycemic agent (OHA) in Japan. It has clinically dual action for increasing insulin secretion and reducing insulin resistance, from Trials of IMeglimin for Efficacy and Safety (TIMES) 1-3. For basic medicine, imeglimin revealed reduction of apoptotic β-cell death with reduced expression for inflammation. Thus, imeglimin may increase insulin granules, bring beneficial efficacy on β-cell mitochondrial morphology and enhance directly insulin secretion from β-cell of the pancreas. Imeglimin has chemical moiety for metformin. Compared with both agents using experiments of dog and mice, lactic acidosis would be lower in imeglimin group.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.